MARATTO

article · JAC-Antimicrobial Resistance

<i>In vitro</i> performance of cost differentiated ceftriaxone brands against <i>Escherichia coli</i>: insights from a tertiary referral hospital in Mbeya, Tanzania

2024Open accessUniversity of Dar es Salaam

Abstract

Despite significant price disparities, low-cost and high-cost ceftriaxone brands demonstrated similar <i>in vitro</i> performance against <i>E. coli</i>. This challenges the notion that higher-priced options offer better performance. Further, <i>in vivo</i> studies are recommended to validate these findings.

Research topics

  • Antibiotic Use and Resistance
  • Pharmaceutical Economics and Policy
  • Pharmaceutical Quality and Counterfeiting

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1093/jacamr/dlae162

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.